Table 2:
Patient outcomes
| Characteristic* | Overall, N = 279 | IC, N = 194 | VEN, N = 85 | p-value |
|---|---|---|---|---|
| Overall Response Rate | 247 / 279 (89%) | 166 / 193 (86%) | 81 / 85 (95%) | 0.019 |
| Composite CR | 243 / 279 (87%) | 166 / 194 (86%) | 77 / 85 (91%) | 0.2 |
| CR | 222 / 279 (80%) | 153 / 194 (79%) | 69 / 85 (81%) | |
| CRh | 4 / 279 (1%) | - | 4 / 85 (5%) | |
| CRi | 17 / 279 (6%) | 13 / 194 (6.7%) | 4 / 85 (5%) | |
| MRD-negative CRc | 0.0028 | |||
| Negative | 150 / 214 (70%) | 86 / 140 (61%) | 64 / 74 (86%) | |
| Positive | 64 / 214 (30%) | 54 / 140 (39%) | 10 / 74 (14% | |
| MLFS | 4 / 279 (1%) | 0 / 194 (0%) | 4 / 85 (5%) | |
| No Response | 26 / 279 (9%) | 23 / 194 (12%) | 3 / 85 (4%) | |
| Early Mortality | 5 / 279 (2%) | 4 / 194 (2%) | 1 / 85 (1%) | |
| 30-day mortality | 4 / 279 (1%) | 3/194 (2%) | 1/85 (1%) | |
| 60-day mortality | 5 / 279 (2%) | 4/194 (2%) | - | |
| Not Evaluable | 1 / 279 (0.4%) | 1 / 194 (0.5%) | - | |
| Time to best response | 31 (27-40) | 32 (27-40) | 29 (27-40) | 0.12 |
| Response by Day 30 | 117 / 247 (47%) | 69 / 166 (42%) | 48 / 81 (58%) | 0.0089 |
| Response by Day 60 | 219 / 247 (89%) | 146 / 166 (88%) | 73 / 81 (90%) | 0.61 |
| ELN Favorable Risk | ||||
| Composite CR | 51 / 53 (96%) | 32 / 32 (100%) | 19 / 21 (90%) | 0.15 |
| MRD-Negative CRc | 40 / 47 (85%) | 23 / 28 (82%) | 17 / 19 (89%) | 0.43 |
| ELN Intermediate Risk | ||||
| Composite CR | 84 / 96 (88%) | 58 / 67 (87%) | 26 / 29 (90%) | 1.0 |
| MRD-Negative CRc | 52 / 71 (73%) | 32 / 47 (68%) | 20 / 24 (83%) | 0.14 |
| ELN Adverse Risk | ||||
| Composite CR | 108 / 130 (83%) | 76 / 95 (80%) | 32 / 35 (91%) | 0.12 |
| MRD-Negative CRc | 58 / 96 (60%) | 31 / 65 (48%) | 27 / 31 (87%) | 0.0059 |